clofutriben
(2)
Sparrow Pharmaceuticals, Inc.
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing clofutriben, an oral, once-daily HSD-1 inhibitor that lowers active cortisol inside specific tissues rather than shutting down the body's steroid system entirely. Founded in 2013 by scientist David Katz, the company has raised roughly $145 million across Series A and Series B rounds and is running the Phase 2b CAPTAIN-T2D trial in patients with type 2 diabetes and elevated cortisol, alongside programs in Cushing's syndrome and autonomous cortisol secretion.
Robert Jacks
Robert Jacks is President & CEO of Sparrow Pharmaceuticals, a Boston-based clinical-stage biopharmaceutical company developing targeted therapies for disorders driven by intracellular cortisol excess. In September 2025 he closed a $95 million Series B co-led by RA Capital and Forbion to advance clofutriben, an HSD-1 inhibitor, through a Phase 2b trial in type 2 diabetes patients with elevated cortisol. A civil engineer turned biotech operator, Jacks has spent 25 years in the industry, co-founded Symbiomix Therapeutics (sold after Solosec NDA approval), previously led Indalo Therapeutics, and has raised more than $300 million across his companies.